Paper Details

  1. Home
  2. Paper Details

Efficacy of rufinamide in childhood refractory epilepsy.

Author: AydınlıNur, BektaşGonca, HızlıZeynep, TatlıBurak, Ulak-ÖzkanMelis, YıldızEdibe Pembegül, ÇalışkanMine, ÖzmenMeral

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated the reliability of rufinamide and its impact on seizure frequency in patients diagnosed with drug-resistant epilepsy. The results showed that rufinamide was effective in patients with Lennox-Gestaut syndrome (LGS) and drop/attacks types of seizures.
Paper Details　
Original Abstract of the Article :
Yıldız EP, Hızlı Z, Bektaş G, Ulak-Özkan M, Tatlı B, Aydınlı N, Çalışkan M, Özmen M. Efficacy of rufinamide in childhood refractory epilepsy. Turk J Pediatr 2018; 60: 238-243. Rufinamide has been used as a new antiepileptic drug in the treatment of drug-resistant epilepsy, in recent years. The objec...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.24953/turkjped.2018.03.002

データ提供：米国国立医学図書館（NLM）

Rufinamide: A Potential Solution for Childhood Refractory Epilepsy

Pediatrics, the branch of medicine dedicated to the care of children, constantly seeks to improve treatment options for childhood illnesses. This research investigates the efficacy of rufinamide, a novel antiepileptic drug, in managing drug-resistant epilepsy in children. The study retrospectively reviewed the data of children diagnosed with drug-resistant epilepsy who received treatment with rufinamide, evaluating its impact on seizure frequency and side effects.

Rufinamide's Effectiveness in Managing Childhood Epilepsy

The study found that rufinamide demonstrated promising results in reducing seizure frequency in children with drug-resistant epilepsy, particularly those with Lennox-Gestaut syndrome. The research highlights the potential of rufinamide as a valuable therapeutic option for managing specific types of epilepsy in children, offering hope for improved seizure control and quality of life.

Navigating Epilepsy Treatment with Rufinamide

This research provides valuable insights into the potential benefits and safety of rufinamide in managing specific types of epilepsy in children. It underscores the need for careful assessment and individualised treatment planning, considering the specific characteristics of the child's epilepsy and the potential risks and benefits of rufinamide therapy. Just as a camel adapts to the desert's harsh environment, finding the right treatment for epilepsy requires a tailored approach that considers the unique needs of each child.

Dr.Camel's Conclusion

This study, like a beacon of hope, shines light on the potential benefits of rufinamide in managing specific types of epilepsy in children. It emphasizes the importance of ongoing research and careful evaluation of novel therapeutic options for improving seizure control and quality of life in children with this challenging condition. This research is a testament to the dedication of healthcare professionals in providing effective treatments for pediatric patients.

Date :
  1. Date Completed 2019-02-25
  2. Date Revised 2019-02-25
Further Info :

Pubmed ID

30511535

DOI: Digital Object Identifier

10.24953/turkjped.2018.03.002

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.